Incretin mimetics are glucose‐lowering medications widely used for the management of type 2 diabetes mellitus (T2D), originally developed based on the glucose‐ and weight‐reducing effects of glucagon‐like peptide‐1 (GLP‐1).1, 2, 3. This evidence concerns the gene GLP1R and diabetes mellitus.